MarketCap
Facebook
X
Telegram
Aerie Pharmaceuticals Operating Income | AERI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Aerie Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -46.4 M | -156 M | -187 M | -210 M | -146 M | -96.9 M | -75.1 M | -50 M | -22.2 M | -6.75 M | -14.2 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.75 M | -210 M | -91.8 M |
Quarterly Operating Income Aerie Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -26.7 M | -18.1 M | -33.6 M | - | -32.4 M | -31.5 M | -34.2 M | - | -33.6 M | -42.6 M | -43.9 M | - | -43.3 M | -46.1 M | -48.2 M | - | -61.3 M | -55.7 M | -40.8 M | - | -32.2 M | -27.8 M | -25.4 M | -28.8 M | -23.3 M | -22.7 M | -22.1 M | -20 M | -17.4 M | -18.1 M | -19.6 M | -16 M | -13.2 M | -11.8 M | -8.98 M | -16 M | -5.69 M | -11.8 M | -8.98 M | -6.75 M | -5.69 M | -5.11 M | -4.62 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.62 M | -61.3 M | -25.4 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ProPhase Labs
PRPH
|
-18 M | - | - | $ 5.07 M |  USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-5.2 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
-1.07 B | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-373 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-18.9 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
OrganiGram Holdings
OGI
|
-35.7 M | $ 0.93 | 1.64 % | $ 88.6 M | Canada |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.46 M | $ 1.14 | -1.72 % | $ 1.92 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Cronos Group
CRON
|
-17.4 M | $ 2.81 | 2.55 % | $ 1.08 B | Canada |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.06 | - | $ 23.8 M | USA |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Canopy Growth Corporation
CGC
|
-162 M | $ 0.89 | -1.82 % | $ 265 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.37 M | $ 6.61 | -5.37 % | $ 98.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
-21.5 M | - | - | $ 150 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-16.3 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Perrigo Company plc
PRGO
|
-1.12 B | $ 10.09 | -0.1 % | $ 1.4 B | USA |
 |
Bausch Health Companies
BHC
|
1.81 B | $ 4.43 | -0.45 % | $ 1.64 B | Canada |
 |
Emergent BioSolutions
EBS
|
100 M | $ 7.26 | -3.2 % | $ 388 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 1.52 | -18.28 % | $ 6.52 M |  China |
 |
Aurora Cannabis
ACB
|
4.95 M | $ 2.67 | -0.74 % | $ 146 M | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 38.45 | -8.19 % | $ 1.41 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 3.73 | -5.81 % | $ 186 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 5.98 | -0.17 % | $ 386 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 6.63 | 1.61 % | $ 239 M | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 7.83 | -1.88 % | $ 685 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 5.18 | -0.38 % | $ 205 M | USA |
 |
Veru
VERU
|
-24.8 M | $ 2.25 | -2.6 % | $ 33 M | USA |
 |
Organogenesis Holdings
ORGO
|
44.7 M | $ 2.39 | -1.65 % | $ 303 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 25.88 | -0.19 % | $ 1.2 B | USA |
 |
Sundial Growers
SNDL
|
-6.35 M | $ 1.25 | -0.4 % | $ 323 M | Canada |
 |
cbdMD
YCBD
|
-2.16 M | $ 0.54 | -6.6 % | $ 2.17 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 3.88 | -2.76 % | $ 2.4 B | Canada |